腫瘍溶解性アデノウイルスの世界市場レポート 2025年

腫瘍溶解性アデノウイルスの市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は8.4%で1,832億2,000万米ドルに成長します。予測期間の成長は、がんの有病率と罹患率の上昇、併用療法の拡大、規制の進歩と承認、ウイルス工学の技術進歩、腫瘍学研究への投資の増加に起因すると考えられます。主な動向としては、ウイルス工学技術の進歩、革新的なドラッグデリバリーシステム、腫瘍を標的とした精度の向上、先進的な免疫療法の併用、患者のモニタリングと診断の強化などが挙げられます。

がん罹患率の上昇は、今後数年間における腫瘍溶解性アデノウイルス市場の拡大を牽引すると予想されます。がんは、制御不能な細胞増殖と身体の他の部位への転移を特徴とする疾患です。人口の高齢化、ライフスタイルの選択、環境暴露、遺伝的素因、検出の進歩などの要因が、がん症例の増加に寄与しています。がん細胞溶解性アデノウイルスは、がん細胞を選択的に標的にして破壊するため、この増大する健康上の課題に対処する有望な治療法となります。例えば、2024年5月、米国の政府機関である国立がん研究所（NCI）は、世界中で約2,000万人の新規がん患者と970万人の死亡者を報告し、2040年の予測は2,990万人の患者数と1,530万人の死亡者数に上昇するとしました。さらに、オーストラリアを拠点とする政府機関であるオーストラリア統計局によると、2023年にはオーストラリア人の1.8％ががんに罹患し、特に75歳以上では男性（2.1％）の罹患率が女性（1.6％）をわずかに上回っています。その結果、がん罹患率の増加が腫瘍溶解性アデノウイルス市場の成長を後押ししています。

腫瘍溶解性アデノウイルス市場で事業を展開する企業は、腫瘍の標的性を高め治療成績を向上させるために、オンコリティック・ウイルス療法と化学療法を統合したVCN-01のような併用療法に注力しています。VCN-01は、がん細胞に選択的に感染して破壊すると同時に、化学療法の効果を高めるように設計された腫瘍溶解性アデノウイルスです。例えば、2024年5月、米国を拠点とする臨床段階の免疫腫瘍学企業であるTheriva Biologics社は、米国食品医薬品局（FDA）が同社の主要候補であるVCN-01にFast Track Designation（FTD）を付与したと発表しました。この指定は、VCN-01とゲムシタビンおよびナブパクリタキセルとの併用による転移性膵腺がんの治療に適用されます。腫瘍溶解性アデノウイルス VCN-01は腫瘍細胞内で複製され、効果的ながん治療の重要な障壁である腫瘍間質の破壊を助ける。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の腫瘍溶解性アデノウイルス PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の腫瘍溶解性アデノウイルス市場：成長率分析
• 世界の腫瘍溶解性アデノウイルス市場の実績：規模と成長, 2019-2024
• 世界の腫瘍溶解性アデノウイルス市場の予測：規模と成長, 2024-2029, 2034F
• 世界の腫瘍溶解性アデノウイルス総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の腫瘍溶解性アデノウイルス市場ウイルスの種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• アデノウイルス5型ベースの腫瘍溶解性ウイルス
• アデノウイルス2型ベースの腫瘍溶解性ウイルス
• その他のウイルスの種類
• 世界の腫瘍溶解性アデノウイルス市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 黒色腫
• 前立腺がん
• 乳がん
• 卵巣がん
• 肺がん
• その他の用途
• 世界の腫瘍溶解性アデノウイルス市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• がん調査機関
• バイオテクノロジー企業
• 学術研究機関
• 世界の腫瘍溶解性アデノウイルス市場アデノウイルス5型に基づく腫瘍溶解性ウイルスのサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 第一世代アデノウイルス5型ベース
• 第2世代アデノウイルス5型ベース
• 遺伝子組み換えアデノウイルス5型ベース
• 世界の腫瘍溶解性アデノウイルス市場アデノウイルス2型をベースとした腫瘍溶解性ウイルスのサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 第一世代アデノウイルス2型ベース
• 第2世代アデノウイルス2型ベース
• 遺伝子組み換えアデノウイルス2型ベース
• 世界の腫瘍溶解性アデノウイルス市場、その他のウイルスタイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 改変アデノウイルス株
• ハイブリッドアデノウイルスの種類
• キメラアデノウイルス

第7章 地域別・国別分析

• 世界の腫瘍溶解性アデノウイルス市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の腫瘍溶解性アデノウイルス市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 腫瘍溶解性アデノウイルス市場：競合情勢
• 腫瘍溶解性アデノウイルス市場：企業プロファイル
  • Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Targovax ASA Overview, Products and Services, Strategy and Financial Analysis
  • CG Oncology Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Replimune Group Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Imugene Limited Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Oncorus Inc.
• PsiOxus Therapeutics Ltd.
• Vyriad Inc.
• Transgene SA
• Valo Therapeutics Oy
• EpicentRx Inc.
• DNAtrix Inc.
• Shanghai Sunway Biotech Co. Ltd.
• TILT Biotherapeutics Ltd.
• Oncolys BioPharma Inc.
• Lokon Pharma AB
• GeneMedicine Co. Ltd.
• Akamis Bio Ltd.
• Genelux Corporation
• SillaJen Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 腫瘍溶解性アデノウイルス市場2029：新たな機会を提供する国
• 腫瘍溶解性アデノウイルス市場2029：新たな機会を提供するセグメント
• 腫瘍溶解性アデノウイルス市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Oncolytic adenovirus is a genetically modified virus designed to selectively target and destroy cancer cells while preserving healthy tissue. It replicates within tumor cells, causing them to rupture and release new viral particles, which continue attacking the cancer. Additionally, it stimulates the immune system, enhancing the body's anti-tumor response.

The primary types of oncolytic adenoviruses include adenovirus type 5-based oncolytic viruses, adenovirus type 2-based oncolytic viruses, and other variants. Adenovirus type 5-based oncolytic viruses are genetically engineered to selectively infect and destroy cancer cells while sparing normal tissues. These viruses are used in the treatment of melanoma, prostate cancer, breast cancer, ovarian cancer, lung cancer, and other malignancies. End-users include hospitals, cancer research institutes, biotechnology companies, and academic and research institutions.

The oncolytic adenovirus market research report is one of a series of new reports from The Business Research Company that provides oncolytic adenovirus market statistics, including the oncolytic adenovirus industry global market size, regional shares, competitors with the oncolytic adenovirus market share, detailed oncolytic adenovirus market segments, market trends, and opportunities, and any further data you may need to thrive in the oncolytic adenovirus industry. This oncolytic adenovirus market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The oncolytic adenovirus market size has grown strongly in recent years. It will grow from $122.31 billion in 2024 to $132.87 billion in 2025 at a compound annual growth rate (CAGR) of 8.6%. The growth during the historic period can be attributed to the rising prevalence of cancer, increasing demand for targeted cancer therapies, growing R&D funding, advancements in delivery methods, and regulatory approvals.

The oncolytic adenovirus market size is expected to see strong growth in the next few years. It will grow to $183.22 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to the rising prevalence and incidence of cancer, the expansion of combination therapies, regulatory advancements and approvals, technological progress in virus engineering, and increased investment in oncology research. Key trends include advancements in viral engineering techniques, innovative drug delivery systems, improved tumor-targeting precision, advanced immunotherapy combinations, and enhanced patient monitoring and diagnostics.

The rising incidence of cancer is expected to drive the expansion of the oncolytic adenovirus market in the coming years. Cancer is a disease characterized by uncontrolled cell growth and its spread to other parts of the body. Factors such as aging populations, lifestyle choices, environmental exposures, genetic predispositions, and advancements in detection contribute to the increasing number of cancer cases. Oncolytic adenoviruses selectively target and destroy cancer cells, presenting a promising therapeutic approach to addressing this growing health challenge. For example, in May 2024, the National Cancer Institute (NCI), a US-based government agency, reported nearly 20 million new cancer cases and 9.7 million deaths worldwide, with projections for 2040 rising to 29.9 million cases and 15.3 million deaths. Additionally, in 2023, the Australian Bureau of Statistics, an Australia-based government agency, reported that 1.8% of Australians had cancer, with males (2.1%) being slightly more affected than females (1.6%), particularly among those aged 75 and older. As a result, the increasing incidence of cancer is fueling growth in the oncolytic adenovirus market.

Companies operating in the oncolytic adenovirus market are focusing on combination therapies such as VCN-01, which integrates oncolytic virotherapy with chemotherapy to enhance tumor targeting and improve therapeutic outcomes. VCN-01 is an oncolytic adenovirus engineered to selectively infect and destroy cancer cells while also increasing the efficacy of chemotherapy. For instance, in May 2024, Theriva Biologics, a US-based clinical-stage immuno-oncology company, announced that the U.S. Food and Drug Administration (FDA) had granted Fast Track Designation (FTD) to its lead candidate, VCN-01. This designation applies to VCN-01 in combination with gemcitabine and nab-paclitaxel for treating metastatic pancreatic adenocarcinoma. The oncolytic adenovirus VCN-01 replicates within tumor cells, helping to break down the tumor stroma, a significant barrier to effective cancer treatment.

In March 2022, Synthetic Biologics, Inc., a US-based biotechnology company, acquired VCN Biosciences for an undisclosed sum. This acquisition strengthens its drug development pipeline by incorporating VCN's clinical-stage drug VCN-01 and preclinical candidate VCN-11, both of which are oncolytic adenoviruses designed to target cancers with high unmet medical needs. VCN Biosciences, S.L. (VCN) is a Spain-based biotechnology company specializing in the development of oncolytic adenoviruses for cancer treatment.

Major players in the oncolytic adenovirus market are Amgen Inc., Targovax ASA, CG Oncology Inc., Replimune Group Inc., Imugene Limited, Oncorus Inc., PsiOxus Therapeutics Ltd., Vyriad Inc., Transgene SA, Valo Therapeutics Oy, EpicentRx Inc., DNAtrix Inc., Shanghai Sunway Biotech Co. Ltd., TILT Biotherapeutics Ltd., Oncolys BioPharma Inc., Lokon Pharma AB, GeneMedicine Co. Ltd., Akamis Bio Ltd., Genelux Corporation, and SillaJen Inc.

North America was the largest region in the oncolytic adenovirus market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in oncolytic adenovirus report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the oncolytic adenovirus market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The oncolytic adenovirus market consists of revenues earned by entities by providing services such as virus engineering and customization, clinical trial management, regulatory consulting, and contract research services. The market value includes the value of related goods sold by the service provider or included within the service offering. The oncolytic adenovirus market also includes sales of therapies, customized viral vectors, and combination therapies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Oncolytic Adenovirus Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on oncolytic adenovirus market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oncolytic adenovirus ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The oncolytic adenovirus market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Virus Type: Adenovirus Type 5-Based Oncolytic Viruses; Adenovirus Type 2-Based Oncolytic Viruses; Other Virus Types
• 2) By Application: Melanoma; Prostate Cancer; Breast Cancer; Ovarian Cancer; Lung Cancer; Other Applications
• 3) By End-User: Hospitals; Cancer Research Institutes; Biotechnology Companies; Academic And Research Institutes
• Subsegments:
• 1) By Adenovirus Type 5-Based Oncolytic Viruses: First-generation Adenovirus Type 5-based; Second-generation Adenovirus Type 5-based; Engineered Adenovirus Type 5-based
• 2) By Adenovirus Type 2-Based Oncolytic Viruses: First-generation Adenovirus Type 2-based; Second-generation Adenovirus Type 2-based; Engineered Adenovirus Type 2-based
• 3) By Other Virus Types: Modified Adenovirus Strains; Hybrid Adenovirus Types; Chimeric Adenoviruses
• Companies Mentioned: Amgen Inc.; Targovax ASA; CG Oncology Inc.; Replimune Group Inc.; Imugene Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Oncolytic Adenovirus Market Characteristics

3. Oncolytic Adenovirus Market Trends And Strategies

4. Oncolytic Adenovirus Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Oncolytic Adenovirus Growth Analysis And Strategic Analysis Framework

• 5.1. Global Oncolytic Adenovirus PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Oncolytic Adenovirus Market Growth Rate Analysis
• 5.4. Global Oncolytic Adenovirus Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Oncolytic Adenovirus Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Oncolytic Adenovirus Total Addressable Market (TAM)

6. Oncolytic Adenovirus Market Segmentation

• 6.1. Global Oncolytic Adenovirus Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adenovirus Type 5-Based Oncolytic Viruses
• Adenovirus Type 2-Based Oncolytic Viruses
• Other Virus Types
• 6.2. Global Oncolytic Adenovirus Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Melanoma
• Prostate Cancer
• Breast Cancer
• Ovarian Cancer
• Lung Cancer
• Other Applications
• 6.3. Global Oncolytic Adenovirus Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Cancer Research Institutes
• Biotechnology Companies
• Academic And Research Institutes
• 6.4. Global Oncolytic Adenovirus Market, Sub-Segmentation Of Adenovirus Type 5-Based Oncolytic Viruses, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• First-generation Adenovirus Type 5-based
• Second-generation Adenovirus Type 5-based
• Engineered Adenovirus Type 5-based
• 6.5. Global Oncolytic Adenovirus Market, Sub-Segmentation Of Adenovirus Type 2-Based Oncolytic Viruses, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• First-generation Adenovirus Type 2-based
• Second-generation Adenovirus Type 2-based
• Engineered Adenovirus Type 2-based
• 6.6. Global Oncolytic Adenovirus Market, Sub-Segmentation Of Other Virus Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Modified Adenovirus Strains
• Hybrid Adenovirus Types
• Chimeric Adenoviruses

7. Oncolytic Adenovirus Market Regional And Country Analysis

• 7.1. Global Oncolytic Adenovirus Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Oncolytic Adenovirus Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Oncolytic Adenovirus Market

• 8.1. Asia-Pacific Oncolytic Adenovirus Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Oncolytic Adenovirus Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Oncolytic Adenovirus Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Oncolytic Adenovirus Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Oncolytic Adenovirus Market

• 9.1. China Oncolytic Adenovirus Market Overview
• 9.2. China Oncolytic Adenovirus Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Oncolytic Adenovirus Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Oncolytic Adenovirus Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Oncolytic Adenovirus Market

• 10.1. India Oncolytic Adenovirus Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Oncolytic Adenovirus Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Oncolytic Adenovirus Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Oncolytic Adenovirus Market

• 11.1. Japan Oncolytic Adenovirus Market Overview
• 11.2. Japan Oncolytic Adenovirus Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Oncolytic Adenovirus Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Oncolytic Adenovirus Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Oncolytic Adenovirus Market

• 12.1. Australia Oncolytic Adenovirus Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Oncolytic Adenovirus Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Oncolytic Adenovirus Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Oncolytic Adenovirus Market

• 13.1. Indonesia Oncolytic Adenovirus Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Oncolytic Adenovirus Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Oncolytic Adenovirus Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Oncolytic Adenovirus Market

• 14.1. South Korea Oncolytic Adenovirus Market Overview
• 14.2. South Korea Oncolytic Adenovirus Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Oncolytic Adenovirus Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Oncolytic Adenovirus Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Oncolytic Adenovirus Market

• 15.1. Western Europe Oncolytic Adenovirus Market Overview
• 15.2. Western Europe Oncolytic Adenovirus Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Oncolytic Adenovirus Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Oncolytic Adenovirus Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Oncolytic Adenovirus Market

• 16.1. UK Oncolytic Adenovirus Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Oncolytic Adenovirus Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Oncolytic Adenovirus Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Oncolytic Adenovirus Market

• 17.1. Germany Oncolytic Adenovirus Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Oncolytic Adenovirus Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Oncolytic Adenovirus Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Oncolytic Adenovirus Market

• 18.1. France Oncolytic Adenovirus Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Oncolytic Adenovirus Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Oncolytic Adenovirus Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Oncolytic Adenovirus Market

• 19.1. Italy Oncolytic Adenovirus Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Oncolytic Adenovirus Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Oncolytic Adenovirus Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Oncolytic Adenovirus Market

• 20.1. Spain Oncolytic Adenovirus Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Oncolytic Adenovirus Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Oncolytic Adenovirus Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Oncolytic Adenovirus Market

• 21.1. Eastern Europe Oncolytic Adenovirus Market Overview
• 21.2. Eastern Europe Oncolytic Adenovirus Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Oncolytic Adenovirus Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Oncolytic Adenovirus Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Oncolytic Adenovirus Market

• 22.1. Russia Oncolytic Adenovirus Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Oncolytic Adenovirus Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Oncolytic Adenovirus Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Oncolytic Adenovirus Market

• 23.1. North America Oncolytic Adenovirus Market Overview
• 23.2. North America Oncolytic Adenovirus Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Oncolytic Adenovirus Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Oncolytic Adenovirus Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Oncolytic Adenovirus Market

• 24.1. USA Oncolytic Adenovirus Market Overview
• 24.2. USA Oncolytic Adenovirus Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Oncolytic Adenovirus Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Oncolytic Adenovirus Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Oncolytic Adenovirus Market

• 25.1. Canada Oncolytic Adenovirus Market Overview
• 25.2. Canada Oncolytic Adenovirus Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Oncolytic Adenovirus Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Oncolytic Adenovirus Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Oncolytic Adenovirus Market

• 26.1. South America Oncolytic Adenovirus Market Overview
• 26.2. South America Oncolytic Adenovirus Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Oncolytic Adenovirus Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Oncolytic Adenovirus Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Oncolytic Adenovirus Market

• 27.1. Brazil Oncolytic Adenovirus Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Oncolytic Adenovirus Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Oncolytic Adenovirus Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Oncolytic Adenovirus Market

• 28.1. Middle East Oncolytic Adenovirus Market Overview
• 28.2. Middle East Oncolytic Adenovirus Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Oncolytic Adenovirus Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Oncolytic Adenovirus Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Oncolytic Adenovirus Market

• 29.1. Africa Oncolytic Adenovirus Market Overview
• 29.2. Africa Oncolytic Adenovirus Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Oncolytic Adenovirus Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Oncolytic Adenovirus Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Oncolytic Adenovirus Market Competitive Landscape And Company Profiles

• 30.1. Oncolytic Adenovirus Market Competitive Landscape
• 30.2. Oncolytic Adenovirus Market Company Profiles
  • 30.2.1. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Targovax ASA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. CG Oncology Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Replimune Group Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Imugene Limited Overview, Products and Services, Strategy and Financial Analysis

31. Oncolytic Adenovirus Market Other Major And Innovative Companies

• 31.1. Oncorus Inc.
• 31.2. PsiOxus Therapeutics Ltd.
• 31.3. Vyriad Inc.
• 31.4. Transgene SA
• 31.5. Valo Therapeutics Oy
• 31.6. EpicentRx Inc.
• 31.7. DNAtrix Inc.
• 31.8. Shanghai Sunway Biotech Co. Ltd.
• 31.9. TILT Biotherapeutics Ltd.
• 31.10. Oncolys BioPharma Inc.
• 31.11. Lokon Pharma AB
• 31.12. GeneMedicine Co. Ltd.
• 31.13. Akamis Bio Ltd.
• 31.14. Genelux Corporation
• 31.15. SillaJen Inc.

32. Global Oncolytic Adenovirus Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Oncolytic Adenovirus Market

34. Recent Developments In The Oncolytic Adenovirus Market

35. Oncolytic Adenovirus Market High Potential Countries, Segments and Strategies

• 35.1 Oncolytic Adenovirus Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Oncolytic Adenovirus Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Oncolytic Adenovirus Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer